Key result
In patients with diabetes admitted for STEMI, having heart failure with preserved ejection fraction was associated with lower in-hospital mortality compared to having heart failure with reduced ejection fraction (adjusted OR 0.635).
Why the study?
Temporal trends in outcomes of STEMI patients with diabetes and either HFrEF or HFpEF had not been fully assessed and compared.
What are the temporal trends and comparative in-hospital outcomes of STEMI patients with diabetes and either HFrEF or HFpEF?
Observational (n=236,733)
Yes
What are the temporal trends and comparative in-hospital outcomes of STEMI patients with diabetes and either HFrEF or HFpEF?
Answers are grounded in this paper and cite their sources.
In STEMI patients with diabetes, those with HFpEF have lower in-hospital mortality and cardiogenic shock compared to those with HFrEF, despite being older and having more comorbidities.
AIMS: We aimed to assess temporal trends in outcomes of ST-elevation myocardial infarction (STEMI) patients with diabetes and heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) and compared both groups. METHODS: Data from the National Inpatient Sample was analyzed between 2005 and 2017. We assessed hospitalizations rate and in-hospital mortality, ventricular tachycardia (VT), ventricular fibrillation (VF), atrial fibrillation (AF), cardiogenic shock (CS), ischemic stroke, acute renal failure (ARF), and revascularization strategy. Socio-economic outcomes consisted of the length of stay (LoS) and total charges/stay. Mortality was stable (around 9%). However, VT, VF, AF, CS, ischemic stroke, and ARF significantly increased with time. In STEMI patients with HFpEF and diabetes, the hospitalization rate significantly increased with time while mean age was stable. The prevalence of comorbidities increased, mortality remained stable (around 4%), but VF, ischemic stroke, and ARF increased with time. Compared to patients with HFrEF, HFpEF patients were 2 years older, more likely to be females, suffered from more cardio-metabolic risk factors, and had a higher prevalence of cardiovascular diseases. However, HFpEF patients were less likely to die [adjusted OR = 0.635 (0.601-0.670)] or develop VT [adjusted OR = 0.749 (0.703-0.797)], VF [adjusted OR = 0.866 (0.798-0.940)], ischemic stroke [adjusted OR = 0.871 [0.776-0.977)], and CS [adjusted OR = 0.549 (0.522-0.577)], but more likely to develop AF [adjusted OR = 1.121 (1.078-1.166)]. HFpEF patients were more likely to get PCI but less likely to get thrombolysis or CABG. Total charges per stay increased by at least 2-fold in both groups. There was a slight temporal reduction over the study period in the LoS of the HFpEF. CONCLUSION: While hospitalizations for STEMI in patients with diabetes and HFpEF followed an upward trend, we observed a temporal decrease in those with HFrEF. Mortality was unchanged in both HF groups despite the temporal increase in risk factors. Nevertheless, HFpEF patients had lower in-hospital mortality and cardiovascular events, except for AF.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2022) conducted an observational in ST-elevation myocardial infarction with diabetes and heart failure (n=236,733). Heart failure with preserved ejection fraction (HFpEF) vs. Heart failure with reduced ejection fraction (HFrEF) was evaluated on In-hospital mortality (OR 0.635, 95% CI 0.601-0.670, p=< 0.001). In patients with diabetes admitted for STEMI, having heart failure with preserved ejection fraction was associated with lower in-hospital mortality compared to having heart failure with reduced ejection fraction (adjusted OR 0.635).
Synapse has enriched 10 related papers. Consider them for comparative context: